Furthermore, AD patients presented with a possible build-up of intracellular Aβ and extracellular tau, evidenced by reduced cognitive test scores for Mini-Mental State Examination (MMSE, 20.0 ± 4.5) and Addenbrooke’s Cognitive Examination (ACE, 58.0 ± 16.5), and elevated CSF Aβ (682.8 ± 216.3 ng/L), alongside higher Functional Activities Questionnaire (FAQ, 11.8 ± 6.2) cognitive test scores, and increased CSF phospho-tau (p-tau, 81.7 ± 25.0 ng/L) and total-tau (t-tau, 520.4 ± 102.4 ng/L) levels. This evidence concerns the gene MAPT and Alzheimer disease.